Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.31 |
| ▸ | LCK | P06239 | 2/20 | 0.31 |
| ▸ | CSF1R | P07333 | 2/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.31 |
| ▸ | KIT | P10721 | 2/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.31 |
| ▸ | FLT1 | P17948 | 2/20 | 0.31 |
| ▸ | KDR | P35968 | 2/20 | 0.31 |
| ▸ | FLT3 | P36888 | 2/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.31 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.31 |
| ▸ | PLK4 | O00444 | 1/20 | 0.31 |
| ▸ | PIR | O00625 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.31 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713691 | 0.82 | JAK2 (0.36) | JAK2CHEK1BRAFCYP3A4CYP2C19 | |
| SCHEMBL1714488 | 0.82 | JAK2 (0.36) | JAK2CHEK1BRAFCYP3A4CYP2C19 | |
| SCHEMBL1714289 | 0.82 | GPR18 (0.43) | JAK2CHEK1BRAFCYP3A4CYP2C19 | |
| SCHEMBL1714283 | 0.82 | GPR18 (0.43) | JAK2CHEK1BRAFCYP3A4CYP2C19 | |
| SCHEMBL1714484 | 0.82 | JAK2 (0.36) | JAK2CHEK1BRAFCYP3A4CYP2C19 | |
| SCHEMBL1713689 | 0.82 | JAK2 (0.36) | JAK2CHEK1BRAFCYP3A4CYP2C19 | |
| SCHEMBL1714505 | 0.79 | JAK2 (0.34) | JAK2BRD4 | |
| SCHEMBL1714502 | 0.79 | JAK2 (0.34) | JAK2BRD4 | |
| SCHEMBL13676714 | 0.79 | CHEK1 (0.55) | CHEK1KDRFLT3SRCMAP2K1 | |
| SCHEMBL12460177 | 0.79 | JAK2 (0.36) | JAK2CHEK1CYP3A4CYP2C19BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-8314121-B2 | Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 | SANOFI (FR) | 2012-11-20 | — | — | US | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253679-A1 | NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 | CDC7, CDK7, CDK17 | JAK2 817/4885CHEK1 17/4885BRAF 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.